Florida Cancer Specialists & Research Institute Leverages Real-World Evidence Capabilities To Advance Blood Cancer Treatment
Txylo.com/10286417

FORT MYERS, Fla., Sept. 6, 2024 ~ At the Society for Hematologic Oncology's 2024 annual meeting in Houston this week, real-world evidence research from Florida Cancer Specialists & Research Institute (FCS) is being presented. FCS President and Managing Physician, Dr. Lucio N. Gordan, spoke about the institute's investments in developing unique datasets that have led to significant insights and improved patient outcomes globally.

Earlier this year, FCS launched a formal effort to collect real-world data from over one million patients and combine it with advanced data science techniques to generate insights that can enhance patient care and aid in the discovery of new therapies. The FCS Real-World Evidence team works with both internal and external partners to provide valuable insights for improving treatment decisions and clinical outcomes based on real-world data.

Dr. Gustavo Fonseca, a medical oncologist and hematologist at FCS, expressed excitement about the institute's contributions to the understanding and treatment of blood cancers and related diseases. He believes that their robust clinical expertise and informatics capabilities make them well-equipped to make significant contributions in this field.

More on Txylo.com

• Lottery.com Inc. Secures $300 Million in Growth Capital, Confirms Nasdaq Compliance & Acquires UAE Sports Incubator Amid High-Profile Brand Exposure
• $750 Million Ketamine Drug Market Withing Reach via New Commissioner's National Priority Vouchers with Anticipated Approval by Year-End for NRx
• NUFABRX awarded Therapeutic Compression agreement with Premier, Inc
• Luxurious Estate in Keenes Pointe Hits the Market at $2.9 Million
• Simplilearn Partners with Michigan Engineering Professional Education to Launch Generative AI Applications for Leaders Program

Amanda Warner, FCS director of real-world evidence, will be presenting a poster titled "Perspectives of single-center community hematologists/oncologists on minimal residual disease testing among patients with multiple myeloma." The research was conducted in partnership with Janssen Scientific Affairs, LLC and co-authored by Dr. Gordan, Trevor Heritage (FCS senior vice president and data officer), Amy Ming (FCS senior director of informatics), and Ernest Griffin (FCS manager of data science).

Another poster abstract presentation will feature research results co-authored by Dr. Gordan, Dr. Fonseca, Trevor Heritage, Amanda Warner, Amy Ming, and Ernest Griffin. The study focuses on the management of patients with lower-risk myelodysplastic syndromes in a large US community oncology practice.

The Society for Hematologic Oncology (SOHO) is the only worldwide society dedicated to hematologic malignancies. The 2024 annual meeting will feature presentations from internationally recognized experts on various topics related to leukemias, lymphomas, myeloma, myelodysplastic neoplasms, myeloproliferative neoplasms, and cellular therapy developments.

FCS's participation in this prestigious event highlights their commitment to advancing the understanding and treatment of blood cancers and related diseases. With their extensive informatics capabilities and real-world evidence research, FCS is making significant contributions to improving patient outcomes and enhancing the discovery of new therapies.

---

Show All News | Report Violation